Other articles

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y stroke

Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure compared with antiplatelet agents to prevent cryptogenic strokes. The most important aspect of this result seems to be the idea that PFO closure in selected patients offers durable benefit with guaranteed long-term safety. The original results from REDUCE

Boletín 116: Cierre Percutáneo del Foramen Oval Permeable

Bulletin 116 ProEducar | Percutaneous Closure of Patent Foramen Ovale

A new edition of the ProEducar Educational Bulletin has arrived for Fellows and interventionists in training. On this occasion, this bulletin addresses in depth the Percutaneous Closure of the Patent Foramen Ovale.   Discover the ProEducar Educational Bulletin HERE (spanish version)

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

ESC 2020 | 2020 Atrial Fibrillation Guidelines: News on Diagnosis, Classification, and Care

New guidelines for the diagnosis and treatment of atrial fibrillation (AF) were released at the 2020 European Society of Cardiology (ESC) virtual congress. This document incorporates several findings from the latest clinical trials, but also represents a great shift in terms of how physicians from different specialties should classify and manage arrhythmia after confirming the

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and symptoms. Mavacamten is the first myosin inhibitor drug of its class. Presented virtually at the European Society of Cardiology 2020 Congress (ESC 2020) and published simultaneously in The Lancet, the EXPLORER-HCM study showed that 37% of patients who received

Recomendaciones de la ACC con el nuevo coronavirus

Procedural Rescheduling Criteria in the Pandemic Era

Patients with structural heart disease are at higher risk in the face of the new coronavirus infection due to both advanced age and numerous comorbidities. All variables must be taken into account when deciding whether a patient can wait (so as to minimize the risk of exposure to the virus) or their pathology must be

Resultados a 5 años del cierre de orejuela

Net Benefit of Left Atrial Appendage Closure vs. Anticoagulation in Atrial Fibrillation

This analysis shows that the long-term clinical benefit of left atrial appendage closure with Watchman is superior to warfarin in patients with atrial fibrillation (AF). The initial peri-procedural risks of device implantation are counterbalanced over time, with reduced risk of bleeding and death.  The PROTECT-AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in

Resultados a 5 años del cierre de orejuela

5-Year Experience of Appendage Closure: More Evidence that Does Not Translate into Clinical Practice

The use of percutaneous left appendage closure increased 3.6-fold from 2011 to 2015, but this volume increase did not entail a significant uptrend of in-hospital events in this “real-world” population in Germany. However, can Germany be considered a real-world setting for Latin America? This question is warranted by the fact that there is no apparent

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y stroke

Long-Term Foramen Ovale Closure after Cryptogenic Stroke

Patent foramen ovale closure is the standard treatment for cryptogenic stroke patients. However, there are is little information on its long-term evolution. The aim of this study was to determine clinical outcomes (death, ischemic or bleeding events) after foramen ovale closure over a 10-year evolution.   The study included 201 consecutive patients (mean age 47

ACC 2019 | POET: los antibióticos vía oral con buenos resultados a largo plazo en endocarditis

ACC 2019 | POET: Oral Antibiotics with Good Long-Term Results for Endocarditis

This work found better survival rates with oral treatment, an outcome that may be credited to shorter hospital stays and the subsequent reduction of complications related to them. A strategy of switching to oral treatment after a short intravenous (IV) regimen confers long-term safety and efficacy. These data are derived from an exploratory analysis of

Evolución de pacientes jóvenes con miocardiopatía hipertrófica tratados con ablación septal por alcoholización.

Contemporary Results for Septal Embolization in Hypertrophic Cardiomyopathy

This work showed that percutaneous septal ablation in patients with symptomatic hypertrophic cardiomyopathy is safe (and improves patient symptoms) and results in excellent long-term survival. Alcohol-induced infarction for treatment of symptomatic hypertrophic obstructive cardiomyopathy is controversial because, while it may relieve acute symptoms, it might also increase long-term mortality.   This study sought to report

Disminuye la profilaxis de endocarditis luego de las guías del 2007

AHA 2018 | Endocarditis Prophylaxis More Limited after AHA 2007 Guidelines

The incidence of infective endocarditis had decreased after AHA 2007 recommendations. At present, some patients are not receiving antibiotic prophylaxis as they should. After AHA restricted the use of antibiotic prophylaxis in 2007, high-risk patients undergoing dental procedures were prescribed less antibiotics. These patients had always been prescribed antibiotic prophylaxis, regardless they had less restrictive